Techniclone Gets FDA Approval
- Share via
TUSTIN — Techniclone Corp. received clearance from the Food and Drug Administration to begin human clinical trials of its radioactive antibody for the treatment of malignant glioma, a type of brain tumor.
The company said it will use a low-pressure catheter to deliver the therapeutic agents to large regions of the brain.
The use of the system, pioneered by the National Institutes of Health, may increase drug uptake and lessen systemic leaking of antibodies from the brain.
The phase I trial will have as many as 24 patients. Techniclone, which develops cancer treatments, is collaborating on the development of the new treatment.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
